Publications by authors named "William Spreen"

Claim this Profile
S
Subcutaneous injections of cabotegravir plus rilpivirine long-acting in virally suppressed adults with HIV-1.
Ronald D'Amico, Kelong Han, Sherene Min, Rebecca DeMoor, Marty St Clair, William Spreen

AIDS· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabotegravir pharmacokinetics in Asians with and without HIV.
Kelong Han, Ahmed A Abulfathi, Rashmi S Mehta, Romina A Nand, Mark A Marzinke, William R Spreen

Int J Clin Pharmacol Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thigh Injections of Cabotegravir + Rilpivirine in Virally Suppressed Adults With HIV-1: A Substudy of the Phase 3b ATLAS-2M Study.
Susan L Ford, Franco Felizarta, Kelong Han, Kehui Wang, Herta Crauwels, William Spreen

Clin Infect Dis· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High-Concentration, Long-Acting Cabotegravir Formulation in Adults Without HIV.
Kelong Han, Paul Benn, Jörg Sievers, David Dorey, Michael Warwick-Sanders, William R Spreen

Clin Pharmacol Drug Dev· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strategies to Manage Dosing Deviations and Interruptions of Cabotegravir Long-Acting Intramuscular Injections.
Kelong Han, Ronald D D'Amico, William R Spreen, Susan L Ford

Clin Pharmacol Drug Dev· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The 96-week outcomes and pharmacokinetics of long-acting cabotegravir plus rilpivirine in South Africans.
Rosie Mngqibisa, Yashna Singh, Catherine Orrell, Johan Lombaard, Sandy Griffith, William Spreen

South Afr J HIV Med· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Weight and Metabolic Changes With Long-Acting Cabotegravir and Rilpivirine or Bictegravir/Emtricitabine/Tenofovir Alafenamide.
Darrell H S Tan, Andrea Antinori, Beng Eu, María José Galindo Puerto, Clifford Kinder, William Spreen

J Acquir Immune Defic Syndr· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir + Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR Study.
Cristina Mussini, Charles Cazanave, Eisuke Adachi, Beng Eu, Marta Montero Alonso, William Spreen

AIDS Behav· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of cabotegravir following intramuscular thigh injections in adults with and without HIV.
Kelong Han, Ronald D D'Amico, William R Spreen, Susan L Ford

Antimicrob Agents Chemother· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SHIV remission in macaques with early treatment initiation and ultra long-lasting antiviral activity.
Michele B Daly, Chuong Dinh, Angela Holder, Donna Rudolph, Susan Ruone, William Spreen

Nat Commun· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP.
Kelong Han, Parul Patel, Scott McCallister, Alex R Rinehart, Yash Gandhi, William Spreen

Antimicrob Agents Chemother· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and tolerability of cabotegravir and rilpivirine long-acting intramuscular injections to the (lateral thigh) muscles of healthy adult participants.
Kelong Han, Hakop Gevorkyan, Jafar Sadik Shaik, Herta Crauwels, Claudia Leemereise, William R Spreen

Antimicrob Agents Chemother· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine.
Parul Patel, Paula Teichner, Emilie Elliot, Marta Boffito, Milena Murray, William R Spreen

Ther Adv Infect Dis· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
Chloe Orkin, Jonathan M Schapiro, Carlo F Perno, Daniel R Kuritzkes, Parul Patel, William R Spreen

Clin Infect Dis· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Moti N Ramgopal, Antonella Castagna, Charles Cazanave, Vicens Diaz-Brito, Robin Dretler, William R Spreen

Lancet HIV· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials.
Parul Patel, Susan L Ford, Mark Baker, Claudia Meyer, Louise Garside, William R Spreen

HIV Med· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.
Edgar T Overton, Gary Richmond, Giuliano Rizzardini, Anders Thalme, Pierre-Marie Girard, William R Spreen

Clin Infect Dis· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of cabotegravir following administration of oral tablet and long-acting intramuscular injection in adult HIV-1-infected and uninfected subjects.
Kelong Han, Mark Baker, Mark Lovern, Prokash Paul, Yuan Xiong, William R Spreen

Br J Clin Pharmacol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspectives of healthcare providers on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings from a Hybrid III Implementation-effectiveness study (CUSTOMIZE).
Maggie Czarnogorski, Cindy P Garris, Marybeth Dalessandro, Ronald D'Amico, Toyin Nwafor, William R Spreen

J Int AIDS Soc· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perspectives of people living with HIV-1 on implementation of long-acting cabotegravir plus rilpivirine in US healthcare settings: results from the CUSTOMIZE hybrid III implementation-effectiveness study.
Cindy P Garris, Maggie Czarnogorski, Marybeth Dalessandro, Ronald D'Amico, Toyin Nwafor, William R Spreen

J Int AIDS Soc· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.
Sinead Delany-Moretlwe, James P Hughes, Peter Bock, Samuel Gurrion Ouma, Portia Hunidzarira, William R Spreen

Lancet· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of Study.
Kenneth C Sutton, Jerome De Vente, Roger Leblanc, Edwin Dejesus, Graham Smith, William R Spreen

Open Forum Infect Dis· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the Potency of Cabotegravir or Rilpivirine.
Jerry L Jeffrey, Marty St Clair, Ping Wang, Chunfu Wang, Zhufang Li, William Spreen

Antimicrob Agents Chemother· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men.
Kelong Han, Paul Wannamaker, Hongzhou Lu, Biao Zhu, Meixia Wang, William R Spreen

Antimicrob Agents Chemother· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study.
Chloe Orkin, Enrique Bernal Morell, Darrell H S Tan, Harold Katner, Hans-Jürgen Stellbrink, William R Spreen

Lancet HIV· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis